- -

Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer

Show simple item record

Files in this item

dc.contributor.author Sirera Pérez, Rafael es_ES
dc.contributor.author Bremnes, Roy M. es_ES
dc.contributor.author Cabrera, Andrea es_ES
dc.contributor.author Jantus Lewintre, Eloisa es_ES
dc.contributor.author Sanmartin, Elena es_ES
dc.contributor.author Blasco, Ana es_ES
dc.contributor.author del Pozo, Nieves es_ES
dc.contributor.author Rosell, Rafael es_ES
dc.contributor.author Guijarro, Ricardo es_ES
dc.contributor.author Galbis, Jose es_ES
dc.contributor.author Sanchez, Jose Javier es_ES
dc.contributor.author Camps, Carlos es_ES
dc.date.accessioned 2017-01-24T12:43:03Z
dc.date.available 2017-01-24T12:43:03Z
dc.date.issued 2011-02
dc.identifier.issn 1556-0864
dc.identifier.uri http://hdl.handle.net/10251/77269
dc.description.abstract Background: Circulating DNA is observed at higher concentrations in patients with lung cancer than in controls. Qualitative and quantitative analysis of circulating DNA is a promising noninvasive tool. Our aim was to prospectively study the association between the catalytic subunit of telomerase (human telomerase reverse transcriptase [hTERT]) in plasma and clinical variables and survival in a large-scale non-small cell lung cancer (NSCLC) study. Methods: Four hundred forty-six patients with stages IIIB and IV NSCLC with a median follow-up of 9.7 months (range, 0.5-45) were analyzed. Blood samples were collected before therapy start (cisplatin/docetaxel). Quantification of baseline circulating DNA was determined as the amount of free hTERT in plasma, by using real-time quantitative polymerase chain reaction. Results: Patients with hTERT ¿49.8 ng/ml (median value) had a median time to progression (TTP) of 6.3 months compared with 4.9 for hTERT more than 49.8 ng/ml (p = 0.001). Overall survival (OS) was significantly higher (10.9 versus 9.3 months) at lower hTERT levels (p = 0.012). When calculations were done using hTERT as continuous variable, we did not observe independent significant differences. Thus, there is an apparent discrepancy in p values when hTERT is considered as a continuous versus dichotomized variable. There was a tendency to differentiate median hTERT levels with respect to response rates (complete response + partial response: 33.1 versus stable disease + progressive disease: 50.7 ng/ml, p = 0.12), but other clinical variables such as age, gender, performance status, stage, histology, and number of metastatic locations were not associated with hTERT. In multivariate analysis, hTERT was an independent prognostic variable for both TTP (hazard ratio: 1.44, p < 0.001) and OS (hazard ratio: 1.33, p = 0.007). Conclusions: In advanced NSCLC, high pretreatment circulating hTERT level is an independent poor prognostic marker for TTP and OS. Circulating DNA is a noninvasive marker, which may help to improve the prognostic profile of these patients. Copyright © 2011 by the International Association for the Study of Lung Cancer. es_ES
dc.description.sponsorship Supported, in part, by the Spanish Society of Medical Oncology (SEOM). en_EN
dc.language Inglés es_ES
dc.publisher Lippincott, Williams & Wilkins es_ES
dc.relation Spanish Society of Medical Oncology (SEOM) es_ES
dc.relation.ispartof Journal of Thoracic Oncology es_ES
dc.rights Reserva de todos los derechos es_ES
dc.subject HTERT es_ES
dc.subject Nonsmall cell lung cancer es_ES
dc.subject NSCLC es_ES
dc.subject Plasma es_ES
dc.subject Prognostic factors es_ES
dc.subject Telomerase es_ES
dc.subject Circulating DNA es_ES
dc.subject Cisplatin es_ES
dc.subject DNA es_ES
dc.subject Docetaxel es_ES
dc.subject Telomerase reverse transcriptase es_ES
dc.subject Unclassified drug es_ES
dc.subject Adult es_ES
dc.subject Advanced cancer es_ES
dc.subject Aged es_ES
dc.subject Article es_ES
dc.subject Blood sampling es_ES
dc.subject Cancer combination chemotherapy es_ES
dc.subject Cancer patient es_ES
dc.subject Cancer staging es_ES
dc.subject Cancer survival es_ES
dc.subject Controlled study es_ES
dc.subject Diagnostic test accuracy study es_ES
dc.subject Enzyme active site es_ES
dc.subject Female es_ES
dc.subject Follow up es_ES
dc.subject Gender and sex es_ES
dc.subject Histology es_ES
dc.subject Human es_ES
dc.subject Lung non small cell cancer es_ES
dc.subject Major clinical study es_ES
dc.subject Male es_ES
dc.subject Multicenter study es_ES
dc.subject Priority journal es_ES
dc.subject Prognosis es_ES
dc.subject Quantitative analysis es_ES
dc.subject Real time polymerase chain reaction es_ES
dc.subject Adenocarcinoma es_ES
dc.subject Aged, 80 and over es_ES
dc.subject Carcinoma, Large Cell es_ES
dc.subject Carcinoma, Non-Small-Cell Lung es_ES
dc.subject Carcinoma, Squamous Cell es_ES
dc.subject DNA, Neoplasm es_ES
dc.subject Follow-Up Studies es_ES
dc.subject Humans es_ES
dc.subject Lung Neoplasms es_ES
dc.subject Middle Aged es_ES
dc.subject Neoplasm Staging es_ES
dc.subject Polymerase Chain Reaction es_ES
dc.subject Prospective Studies es_ES
dc.subject Survival Rate es_ES
dc.subject Tumor Markers, Biological es_ES
dc.subject.classification MICROBIOLOGIA es_ES
dc.title Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1097/JTO.0b013e31820189a5
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural es_ES
dc.description.bibliographicCitation Sirera Pérez, R.; Bremnes, RM.; Cabrera, A.; Jantus Lewintre, E.; Sanmartin, E.; Blasco, A.; Del Pozo, N.... (2011). Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology. 6(2):286-290. doi:10.1097/JTO.0b013e31820189a5 es_ES
dc.description.accrualMethod Senia es_ES
dc.relation.publisherversion https://dx.doi.org/10.1097/JTO.0b013e31820189a5 es_ES
dc.description.upvformatpinicio 286 es_ES
dc.description.upvformatpfin 290 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 6 es_ES
dc.description.issue 2 es_ES
dc.relation.senia 221101 es_ES


This item appears in the following Collection(s)

Show simple item record